Nevada
|
0-30379
|
88-0425691
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
||
Common Stock, $0.01 par value
|
CEMI
|
The NASDAQ Stock Market LLC
|
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Item 9.01 |
Financial Statements and Exhibits.
|
(d)
|
Exhibits.
|
Exhibit
|
|
Description
|
Letter agreement dated January 17, 2020, between Chembio Diagnostics, Inc. and Gail S. Page
|
†
|
Indicates management contract or compensatory plan.
|
Chembio Diagnostics, Inc.
|
||
Dated: January 21, 2020
|
By:
|
/s/ Neil A. Goldman
|
Executive Vice President and Chief Financial Officer
|
January 17, 2020
|
|
1.
|
Duties. During the Term, you will have all of the duties, responsibilities and authority commensurate with the position of Chief Executive Officer, including such duties, responsibilities and
authority as may from time to time be assigned to you by the Company’s Board of Directors (the “Board”). You agree to serve the Company faithfully, diligently and competently, and to devote
your full working time, energy and skill to the Company’s business. Notwithstanding the foregoing, you will be permitted to:
|
(a)
|
continue to serve as a member of the public or private company boards of directors on which you currently serve; and
|
(b)
|
serve in any capacity with any professional, educational, philanthropic, public interest, charitable or community organization;
|
2. |
Term. The Term will continue until the effective date of the appointment of a permanent CEO, unless earlier terminated by a vote of the majority of independent directors.
|
3. |
Compensation.
|
(a)
|
Base Salary. The Company will pay you a base salary at an annualized rate of $460,000 for your services during the Term, less applicable withholdings for taxes,
payable in accordance with the Company’s customary payroll practices from time to time in effect.
|
(b)
|
Equity Award. In connection with your services as Interim CEO, the Company has delivered to you a Notice of Grant of Restricted Stock Award, dated as of January
17, 2020, with respect to a total of 30,864 shares of restricted common stock of the Company, which will vest as set forth therein.
|
(c)
|
Reimbursements. The Company will reimburse you on a tax-neutral basis for all reasonable out‑of-pocket business, entertainment and travel expenses in connection
with the performance of your duties under this Agreement (including travel to the Company’s headquarters in New York) that are incurred and submitted in accordance with the Company’s expense reimbursement policy from time to time in
effect or with other guidelines approved by, or other approval of, a majority of the disinterested directors.
|
(d)
|
Benefits. During the Term you will be entitled to participate in such privileges and in such insurance and other benefit programs (other than the Company’s
long-term incentive programs) as are generally made available to the Company’s senior executives, to the extent you meet the eligibility requirements for such privileges and programs.
|
4.
|
At-Will Employment. Your employment with the Company will be “at-will” and may be terminated by you or the Company (in accordance with Section 2) at any time with or without notice for any (or no)
reason. You will not have any contractual right to severance benefits in connection with any termination of your service as Interim CEO, except as may be otherwise determined by the Board (or its Compensation Committee) in its sole
discretion.
|
5.
|
Transition Period.
|
(a)
|
Transition Services. You agree that you will make yourself reasonably available to consult with representatives of the Company on transition matters for a
period of sixty calendar days following the end of the Term (the “Transition Period”).
|
(b)
|
Compensation. The Company will pay you transition service fees at an annualized rate of $460,000 for your services during the Transition Period.
|
(c)
|
Reimbursements. For clarity, the Company confirms that the provisions of Section 3(c) will continue to apply throughout the Transition Period.
|
6.
|
Confidential Information and Company Records.
|
(a)
|
Confidentiality. During the Term and the Transition Period, and continuing thereafter, you agree that you will not, whether alone or in association with any
other person, directly or indirectly, knowingly divulge, furnish or make accessible to any third person or organization other than in the regular course of the Company’s business any confidential information concerning the Company or
its subsidiaries or its or their business, including confidential methods of operation and organization, confidential sources of supply and customer or other mailing lists.
|
(b)
|
Records. All records, files, documents and the like, or abstracts, summaries or copies thereof, relating to the business of the Company or the business of any
subsidiary or affiliated companies, which the Company or you prepare or use or come into contact with, will remain the sole property of the Company or the affiliated or subsidiary company, as the case may be, and will be promptly
returned upon termination of the Transition Period or at such earlier time as may be requested by the Board.
|
(c)
|
Enforcement. The provisions of this Section 6 shall survive the end of the Term and the end of the Transition Period. You acknowledge that any remedy at law for
a breach or threatened breach of any of the provisions of this Section 6 may be inadequate and that accordingly the Company shall be entitled to an injunction or specific performance or any other mode of equitable relief without the
necessity of showing any actual damage, posting a bond or furnishing other security.
|
7.
|
Company Policies. You will be bound by and comply fully with the Company’s standard confidentiality agreement (a form of which was been provided to you), insider trading policy, code of business
conduct and ethics, and any other policies and programs adopted by the Company regulating the behavior of its employees, as such policies and programs may be amended from time to time to the extent the same are not inconsistent with
this Agreement.
|
8.
|
Indemnification. To the maximum extent permitted by law, you will be indemnified under the Company’s Articles of Incorporation and Bylaws while serving as Interim CEO, and you will continue to be
named as an insured on the director and officer liability insurance policy currently maintained by the Company, or as may be maintained by the Company from time to time.
|
9.
|
Miscellaneous.
|
(a)
|
Notices. Notices under this Agreement must be in writing and will be deemed to have been given when personally delivered or two days after mailed by U.S.
registered or certified mail, return receipt requested and postage prepaid. Mailed notices to you will be addressed to you at the home address that you have most recently communicated to the Company in writing. Notices to the Company
will be addressed to the Chair of the Board at the Company’s corporate headquarters. Either party hereto may change its address for the purpose of this Section 9(a) by written notice similarly given.
|
(b)
|
Successors. This Agreement is binding on and may be enforced by the Company and its successors and permitted assigns and is binding on and may be enforced by you and your heirs and legal
representatives. Any successor to the Company or substantially all of its business (whether by purchase, merger, consolidation or otherwise) will in advance assume in writing and be bound by all of the Company’s obligations under
this Agreement and shall be the only permitted assignee.
|
(c)
|
Waiver. No provision of this Agreement may be modified or waived except in writing signed by you and a duly authorized officer of the Company.
|
(d)
|
Severability. The invalidity, illegality or unenforceability of any provision or provisions of this Agreement shall not affect any other provision of this
Agreement, which shall remain in full force and effect, nor shall the invalidity, illegality or unenforceability of a portion of any provision of this Agreement affect the balance of such provision. In the event that any one or
more of the provisions contained in this Agreement or any portion thereof shall for any reason be held to be invalid, illegal or unenforceable in any respect, this Agreement shall be reformed, construed and enforced as if such
invalid, illegal or unenforceable provision had never been contained in this Agreement.
|
(e)
|
Survival. The provisions of this Agreement shall survive the termination of your employment for any reason to the extent necessary to enable the parties to enforce their respective rights
under this Agreement.
|
(f)
|
Entire Agreement. This Agreement, together with the Notice of Grant of Restricted Stock Award referenced in Section 3(b), constitute the entire understanding and agreement you and between
the Company regarding your service as Interim CEO and your transition services during the Transition Period. This Agreement supersedes all prior negotiations, discussions, correspondence, communications, understandings and
agreements between you and the Company relating to such service and transition services.
|
(g)
|
Modifications. This Agreement may not be modified or amended, nor may any rights under it be waived, except in a writing signed and agreed to by both you and a majority of the
disinterested directors of the Company.
|
(h)
|
Interpretation. For purposes of this Agreement:
|
(i)
|
headings used in this Agreement are for convenience of reference only and shall not, for any purpose, be deemed a part of this Agreement;
|
(ii)
|
the word “including” as used in this Agreement shall not be construed so as to exclude any other thing not referred to or described; and
|
(iii)
|
this Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted.
|
(i)
|
Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO AGREEMENTS MADE AND TO BE
PERFORMED IN THAT STATE, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW.
|
Chembio Diagnostics, Inc.
|
||
By:
|
/s/ Neil A. Goldman
|
|
Executive Vice President and Chief Financial Officer
|
||
|
Accepted and agreed:
|
|
|
|
Gail S. Page
|
|
|
|
/s/ Gail S. Page
|